Amundi Exelixis, Inc. Transaction History
Amundi
- $253 Billion
- Q2 2024
A detailed history of Amundi transactions in Exelixis, Inc. stock. As of the latest transaction made, Amundi holds 25,033 shares of EXEL stock, worth $649,856. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,033
Previous 31,314
20.06%
Holding current value
$649,856
Previous $743,000
24.36%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding EXEL
# of Institutions
460Shares Held
240MCall Options Held
2.04MPut Options Held
1.29M-
Black Rock Inc. New York, NY33.5MShares$870 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.7MShares$770 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA27.1MShares$704 Million2.95% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.2MShares$394 Million0.6% of portfolio
-
State Street Corp Boston, MA12.6MShares$327 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $8.35B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...